Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 9, 2011, Pages 1925-1927

  Vermeulen, Roel ^a   Hosnijeh, Fatemeh Saberi ^a,b   Portengen, Luẗzen ^a   Krogh, Vittorio ^c   Palli, Domenico ^d   Panico, Salvatore ^e   Tumino, Rosario ^f   Sacredote, Carlotta ^g   Purdue, Mark ^h   Lan, Qing ^h   Rothman, Nathaniel ^h   Vineis, Paolo ^g,i  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Scientific Institute of Tuscany   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Ragusa Cancer Registry   (Italy)

^g Human Genetics Foundation   (Italy)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B CELL LYMPHOMA; BLOOD LEVEL; BLOOD SAMPLING; BLOOD VOLUME; CANCER RISK; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHOMA; MALE; PRIORITY JOURNAL; REPLICATION STUDY;

ANTIGENS, CD30; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 80052546342     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0396     Document Type: Article

References (12)

1. Ambinder R.F., Bhatia K., Martinez-Maza O., Mitsuyasu R. Cancer biomarkers in HIV patients. Curr Opin HIV AIDS 2010;5:531-537
2. Vendrame E., Martinez-Maza O. Assessment of pre-diagnosis biomarkers of immune activation and inflammation: Insights on the etiology of lymphoma. J Proteome Res 2011;10:113-119
3. Breen E.C., Fatahi S., Epeldegui M., Boscardin W.J., Detels R., Martínez- Maza O. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol 2006; 27:187-194
4. Purdue M.P., Lan Q., Martinez-Maza O., Oken M.M., Hocking W., Huang W-Y, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 2009;114:2730-2732
5. Riboli E., Hunt K.J., Slimani N., Ferrari P., Norat T., Fahey M., et al. European prospective investigation into cancer and nutrition (EPIC): Study populations and data collection. Public Health Nutr 2002;5:1113-1124 (Pubitemid 36313608)
6. Saberi Hosnijeh F., Krop E.J.M., Scoccianti C., Krogh V., Palli D., Panico S., et al. Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): A case-control study nested in the Italian European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2010;19:1577-1584
7. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
8. Morton L.M., Turner J.J., Cerhan J.R., Linet M.S., Treseler P.A., Clarke C.A., et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110: 695-708. (Pubitemid 47105409)
9. Figueiras A., Cadarso-Suárez C. Application of nonparametric models for calculating odds ratios and their confidence intervals for continuous exposures. Am J Epidemiol 2001;154:264-275 (Pubitemid 32701163)
10. Croft M. Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity. Nat Rev Immunol 2003;3:600-620
11. Kennedy M.K., Willis C.R., Armitage R.J. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006;118: 143-152 (Pubitemid 43727419)
12. Rezaei N., Haji-Molla-Hoseini M., Aghamohammadi A., Pourfathollah A.A., Moghtadaie M., Pourpak Z. Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications. J Clin Immunol 2008;28:78-84.